Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.Shaohua Li, Rong Guo, Chong Zhong et al.|Journal of Clinical Oncology|2021Cited by 30
Long noncoding RNA TINCR facilitates hepatocellular carcinoma progression and dampens chemosensitivity to oxaliplatin by regulating the miR-195-3p/ST6GAL1/NF-κB pathwayJie Mei, Rong Guo, Yuhao Tang et al.|Journal of Experimental & Clinical Cancer Research|2022Cited by 30
Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic StudyJie Mei, Rong Guo, Shaohua Li et al.|Frontiers in Oncology|2020Cited by 17
Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: A preliminary report of a phase III, randomized, controlled clinical trial.Shaohua Li, Rong Guo, Wei Wei et al.|Journal of Clinical Oncology|2020Cited by 11
Comparison of anti–PD-L1 with anti–PD-1 antibodies in the combination of HAIC and lenvatinib for the treatment of unresectable hepatocellular carcinoma.Shaohua Li, Rongping Guo, Jie Mei et al.|Journal of Clinical Oncology|2023Cited by 3